Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation
Ишемический инсульт у пациентов с фибрилляцией предсердий несмотря на терапию пероральными антикоагулянтами
2020-02-13
SCID: 54.1/hkvt4gm9
Discuss with AI
atrial fibrillationdirect oral anticoagulantsischemic strokeoral anticoagulant therapyrecurrent stroke
Figures from the paper
Abstract (AI)
Objective It is not known whether patients with atrial fibrillation (AF) with ischemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how ongoing secondary prevention should be managed. Methods We conducted an individual patient data pooled analysis of 7 prospective cohort studies that recruited patients with AF and recent cerebral ischemia. We compared patients taking oral anticoagulants (vitamin K antagonists [VKA] or direct oral anticoagulants [DOAC]) prior to index event (OAC prior ) with those without prior oral anticoagulation (OAC naive ). We further compared those who changed the type (ie, from VKA or DOAC, vice versa, or DOAC to DOAC) of anticoagulation (OAC changed ) with those who continued the same anticoagulation as secondary prevention (OAC unchanged ). Time to recurrent acute ischemic stroke (AIS) was analyzed using multivariate competing risk Fine–Gray models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Results We included 5,413 patients (median age = 78 years [interquartile range (IQR) = 71–84 years]; 5,136 [96.7%] had ischemic stroke as the index event, median National Institutes of Health Stroke Scale on admission = 6 [IQR = 2–12]). The median CHA 2 DS 2 ‐Vasc score (congestive heart failure, hypertension, age≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) was 5 (IQR = 4–6) and was similar for OAC prior (n = 1,195) and OAC naive (n = 4,119, p = 0.103). During 6,128 patient‐years of follow‐up, 289 patients had AIS (4.7% per year, 95% CI = 4.2–5.3%). OAC prior was associated with an increased risk of AIS (HR = 1.6, 95% CI = 1.2–2.3, p = 0.005). OAC changed (n = 307) was not associated with decreased risk of AIS (HR = 1.2, 95% CI = 0.7–2.1, p = 0.415) compared with OAC unchanged (n = 585). Interpretation Patients with AF who have an ischemic stroke despite previous oral anticoagulation are at a higher risk for recurrent ischemic stroke despite a CHA 2 DS 2 ‐Vasc score similar to those without prior oral anticoagulation. Better prevention strategies are needed for this high‐risk patient group. ANN NEUROL 2020;87:677–687
Key Findings
1
Changing anticoagulant type after the index stroke was not associated with reduced recurrent ischemic stroke risk compared with continuing the same anticoagulant (HR 1.2, 95% CI 0.7–2.1).
2
Patients who experienced ischemic stroke despite prior oral anticoagulation had a significantly higher recurrent stroke risk than anticoagulation-naive patients (HR 1.6, 95% CI 1.2–2.3).
3
Recurrent acute ischemic stroke occurred at a rate of 4.7% per year during 6,128 patient-years of follow-up.
4
The findings indicate that ischemic stroke despite anticoagulation identifies patients with atrial fibrillation at particularly high risk of further ischemic stroke, while switching anticoagulants did not demonstrate clear benefit.
5
This pooled analysis included 5,413 patients with atrial fibrillation and recent cerebral ischemia from seven prospective cohort studies.
Research Object
Patients with atrial fibrillation and recent ischemic stroke, including those with stroke despite prior oral anticoagulant therapy
Research Subject
Risk of recurrent acute ischemic stroke and the association of changing versus continuing oral anticoagulation for secondary prevention
Publication Details
Publication Date
2020-02-13
Journal
Publisher
ISSN
Cited by
255
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest